Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03742154 · ClinicalTrials.gov registry record · Early Phase 1
Hollings Cancer Center Varenicline Sampling Study
A Early Phase 1 study of Smoking Cessation and Smoking, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 99
- Enrollment target
- 1
- Study location
NCT03742154: Completed Early Phase 1 study of Smoking Cessation and Smoking, sponsored by Medical University of South Carolina.
NCT03742154 is a Early Phase 1 study of Smoking Cessation and Smoking that has completed, run by Medical University of South Carolina. The registered enrollment target is 99 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03742154, a Early Phase 1 study of Smoking Cessation and Smoking, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 99 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn what happens when people are given a free, 4-week, sample of varenicline, a smoking cessation medication. Investigators will look at quit attempts, changes in smoking, and attitude towards varenicline, in both smokers who want to quit and those who do not. Smoking use causes a number of deaths and diseases, including heart disease and cancer. All smokers are advised to quit. Varenicline (sometimes called Chantix), is a prescription medication approved by the US FDA. Many studies show that use of varenicline can help smokers quit smoking. Varenicline is a prescription medication, which usually means that people have to see a doctor to get it. This study examines a different way to deliver varenicline, delivered directly to participants for a few weeks, and without need to see a doctor. This method is called "varenicline sampling." The study is sponsored by the Hollings Cancer Center at the Medical University of South Carolina. The study is being done at the Medical University of South Carolina, but study recruitment is based state-wide, throughout South Carolina.
Primary Outcome
Percent of participants with any self-defined and any self-defined 24-hr quit attempt
Conditions Studied
Interventions
- DRUG Varenicline 0.5 MG
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2020-04-06 |
| Phase | Early Phase 1 |
What the finished NCT03742154 record still lists
NCT03742154 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (79% lower).
The record links to 4 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which Varenicline 0.5 MG is the first listed.
NCT03742154 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT03742154 about?
NCT03742154 is a clinical study titled "Hollings Cancer Center Varenicline Sampling Study". The purpose of this study is to learn what happens when people are given a free, 4-week, sample of varenicline, a smoking cessation medication. Investigators will look at quit attempts, changes in smoking, and attitude towards varenicline, in both smokers who want to quit and those who do not. Smok...
What is the current status of trial NCT03742154?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 99 participants. The study started on 2018-12-03. Estimated completion is 2020-04-06.
What conditions does trial NCT03742154 study?
This clinical trial studies the following conditions: Smoking Cessation, Smoking, Smoking, Cigarette, Smoking, Tobacco.
What interventions are being tested in trial NCT03742154?
The interventions under investigation include: Varenicline 0.5 MG (DRUG).
Who is sponsoring clinical trial NCT03742154?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03742154 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03742154's enrollment target sits among peer trials
99 119th of 188 higher than 70 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Smoking Cessation Treatment for Head & Neck Cancer Patients
ACTIVE NOT RECRUITING · Early Phase 1
-
End Nicotine Dependence Clinic
COMPLETED · Early Phase 1
-
Applying mHealth to Tobacco-related Health Disparities
COMPLETED · Early Phase 1
-
Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder
COMPLETED · Early Phase 1
-
Smoking by IV Pulsed Nicotine
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI